Eventide Asset Management, LLC 13D and 13G filings for Lexeo Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 12:03 pm Sale |
2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Eventide Asset Management, LLC | 1,234,834 3.730% |
-621,152 (-33.47%) |
Filing |
| 2024-11-14 12:23 pm Sale |
2024-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Eventide Asset Management, LLC | 1,855,986 5.610% |
-336,225 (-15.34%) |
Filing |
| 2024-08-09 09:43 am Sale |
2024-07-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Eventide Asset Management, LLC | 2,192,211 6.650% |
-810,620 (-27.00%) |
Filing |
| 2023-12-11 5:13 pm Purchase |
2023-11-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Eventide Asset Management, LLC | 3,002,831 11.930% |
3,002,831 (New Position) |
Filing |